Article

Prepare for hyperopic shift following DSAEK graft surgery

A retrospective study including 45 eyes that underwent Descemet's stripping automated endothelial keratoplasty (DSAEK) found an average refractive change of +0.88 D after surgery. That hyperopic shift after DSAEK has implications for management of patients undergoing cataract surgery simultaneously with or after DSAEK and for anticipating refractive outcomes in pseudophakic patients undergoing DSAEK.

Durham, NC-Results of a retrospective study evaluating refractive change after Descemet’s stripping automated endothelial keratoplasty (DSAEK) surgery show a hyperopic shift, said Bokkwan Jun, MD, PhD.

"Further studies are warranted to evaluate the refractive change after longer follow-up and to understand its mechanism," said Dr. Jun, research associate, Duke University Eye Center, Durham, NC.

"However, based on our observations, we recommend considering adjusting the IOL power in patients undergoing a DSAEK triple procedure (DSAEK, phacoemulsification, IOL implantation) and in DSAEK patients undergoing cataract surgery," he said.

"This information may also aid in anticipating refractive outcomes after pseudophakic DSAEK surgery," he said.

Dr. Jun and colleagues conducted a retrospective review of all cases of DSAEK surgery performed by three surgeons at the Duke University Eye Center between August 2005 and December 2006, to investigate the occurrence of a postoperative refractive change and any correlations with graft thickness and diameter. Eyes were excluded from the study if any DSAEK complications developed, such as graft failure or rejection, or if they had a noncorneal condition that would affect visual acuity, such as glaucoma or retinal pathology.

Data were analyzed for a total of 45 cases of 44 patients who had at least 3 months follow-up after DSAEK as well as spherical equivalent data available from a manifest refraction performed preoperatively and at last follow-up. Fuchs’ endothelial dystrophy was the underlying diagnosis in the majority of eyes (89%), and the remaining cases were treated with DSAEK for pseudophakic bullous keratopathy/bullous keratopathy. Almost two-thirds of eyes were pseudophakic at the time of DSAEK (28 eyes, 62%) and the rest (17 eyes, 38%) underwent DSAEK triple surgery. The average age of patients in the study was 68 years (range, 15 to 81 years).

The overall refractive change in the 45 eyes was +0.88 D. After subgroup classification, the mean refractive change was +1.15 D in 17 eyes that underwent DSAEK triple surgery and +0.71 D in 28 pseudophakic DSAEK eyes. The difference between the two groups was not statistically significant.

Read the complete article in the Oct. 1, 2008 issue of Ophthalmology Times.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.